---
search:
  boost: 2 
---

# Hematopoietic Agents

This is a subcategory of Blood Formation, Coagulation, and Thrombosis Agents.

## Decision Tree

- [Hematopoietic Agents- Preferred Agents - Epogen, Mircera, Retacrit](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMDQwWE44MTUyTlk5VEo2VEJQS1NPN1JBRyQlQCN0PWcu&topview=Preview)

- [Hematopoietic Agents- Non-Preferred Agents - Procrit](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNlJSMVUwTVFaWFpUNjBCVlAzTlJYTzNNRCQlQCN0PWcu&topview=Preview)

- [Hematopoietic Agents- Non-Preferred Agents - Aranesp](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUOEI3MlUwUjJHQ1IyTURBTkVZREFRRDZVQSQlQCN0PWcu&topview=Preview)

## Formulary

### Preferred

| Preferred              | Generic Name | Quantity | Time (Days) |
| :--------------------- | :----------- | :------: | :---------: |
| Epogen <sup>PA</sup>   |              |          |             |
| Mircera <sup>PA</sup>  |              |          |             |
| Retacrit <sup>PA</sup> |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Aranesp       |              |          |             |
| Procrit       |              |          |             |

## Authorizations

**Length of Authorizations**: Dependent upon diagnosis below

### Approval of epoetin alfa or darbepoetin

| Diagnosis                                                    | Hemoglobin Level | Approval Length |
| ------------------------------------------------------------ | ---------------- | --------------- |
| Anemia due to chronic renal failure, patient on dialysis     | ≤11            | 365 days        |
| Anemia due to chronic renal failure, patient not on dialysis | ≤10            | 365 days        |
| Chemotherapy-induced anemia                                  | ≤10            | 90 days         |
| Anemia in myelodysplastic syndrome                           | ≤11            | 180 days        |

### Approval of epoetin alfa only

| Diagnosis                                                                           | Hemoglobin Level | Approval Length |
| ----------------------------------------------------------------------------------- | ---------------- | --------------- |
| Autologous blood donation, patient will require blood transfusions                  | \>10, ≤13      | 30 days         |
| Anemia of prematurity, age \<=6 months                                              | N/A              | 42 days         |
| Anemia associated with chronic inflammatory disorders (e.g., rheumatoid arthritis)  | ≤11            | 180 days        |
| Anemia associated with ribavirin combination therapy in hepatitis Cinfected patient | ≤11            | 180 days        |
| Anemia in zidovudine-treated HIV-infected patients                                  | ≤11            | 180 days        |

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
  - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage
formulation
- Must have had an inadequate clinical response of at least **14 days** with at least **one preferred** drug
  - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
  - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization 

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=14)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=9)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
